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ABSTRACT
Allergic bronchial asthma is a complex inflammatory diseases originated from dysregulated immune responses
in the respiratory mucosa. The inflammatory state in asthmatic lung is characterized by massive infiltration with
eosinophils, lymphocytes, and mast cells in the airway mucosa leading to airway hyperseisitivity, goblet cell hy-
perplasia and mucus overproduction. The inflammatory process is thought to be the result of intensive T helper
(Th) 2-biased immune response. Over the past several years, there has been enormous progress in under-
standing the mechanisms for development of Th2-biased responses after inhaled exposure to allergens and
the characteristics of CD4+ T cells prominently involved in this process. Recently, a new population of T cells,
invariant natural killer T (iNKT) cells has been shown to play an important role in the pathogenesis of mouse
model of allergic airway inflammation. iNKT cells are one of the most potent immune modulators through a
massive production of a various cytokines including IL-4 and IFN-γ upon activation, and are involved in a vari-
ety of immunoregulations including infection, autoimmunity, and tumor surveillance. The potent pathogenic role
of iNKT cells in the development of bronchial asthma is due to their ability to produce predominant Th2 cytoki-
nes in a given condition. The involvement of iNKT cells in the pathogenesis of asthma might have been under-
estimated in the past studies demonstrating the involvement of CD4+ T cells in asthma because of the difficulty
in the detection of iNKT cells. Meanwhile, growing evidences have demonstrated that iNKT cells could be a
promising target for immune-based therapies for autoimmune diseases, tumor, and infection due to the invari-
ance of their TCR usage, the restriction to the evolutionally-conserved non-polymorphic antigen-presenting
molecule CD1d, and their outstanding ability to produce both Th1- and Th2-cytokines. In this review, we will
overview current understanding of the pathophysiological roles of iNKT cells in asthma. We would also discuss
on possible therapeutic approaches to bronchial asthma employing glycolipid ligands for iNKT cells.
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INTRODUCTION
Accumulating evidence has verified the critical role of
the cytokine milieu in a wide variety of immune re-
sponses in vivo. Especially, Th1 cells producing
IFN-γ, IL-2, and TNF-α are important for cell-
mediated immunity and eliminate intracellular patho-
gen. Meanwhile, Th2 cells producing IL-4, IL-5, and
IL-13 control humoral immunity to helminthic para-
sites and are believed to be responsible for initiation
and perpetuation of allergic asthma.1 In addition, IFN-
γ and IL-4 themselves are involved in the differentia-
tion of Th1 and Th2 cells, respectively2 and these two
subsets of helper T cells cross-regulate each other.
Therefore, fine-tuning of Th1Th2 balance is essen-
tial for avoiding host-threatening immune dysfunc-
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tion. Excessive Th1- and Th2-response to specific an-
tigens has been shown to cause the process leading
to the pathogenesis of autoimmune or allergic dis-
eases, respectively. Allergic bronchial asthma is a
complex inflammatory disease caused by superfluous
immune response to inhaled exogenous allergen in
the respiratory mucosa.3 The inflammatory state in
asthmatic lung is characterized by massive infiltration
with eosinophils, lymphocytes, and mast cells in the
airway wall concomitant with a various Th2 cytokines
such as IL-4, IL-5, and IL-13, which orchestrate the re-
cruitment and activation of T cells, B cells, eosino-
phils, and mast cells. There has been tremendous
progress in understanding the mechanisms for devel-
opment of Th2-biased responses after inhaled expo-
sure to allergens and the characteristics of Th2 cells
prominently involved in this process. For example,
IL-13 has been shown to be a potent initiator of an in-
flammatory response, goblet cell hyperplasia, airway
hyperresponsiveness (AHR), and airway fibrosis.4
More recently, two molecules, thymic stromal lym-
phopoietin (TSLP)5,6 and Interleukin-25 (IL-25),7,8 are
shown to be relevant to the development of Th2-
driven inflammation and the pathogenesis of asthma.
Furthermore, the studies on protective immunity to
asthma have been focusing on the role of TGF-β ex-
pressed on regulatory T cells and following activation
of NotchHES-1signaling on tolerance induction in
the lung.9 Recently, a new population of T cells, in-
variant natural killer T (iNKT) cells has been shown
to be involved in the pathogenesis of asthma possibly
by enhancing Th2 response in animal models of aller-
gic airway inflammation and in asthma patients.10
Current understanding of the pathophysiologic roles
of iNKT cells in asthma and possible therapeutic ap-
proaches employing glycolipid ligand for iNKT cells
will be overviewed and discussed in the following sec-
tions. The elucidation of the precise immunological
relevance of iNKT cells in allergic asthma will be
helpful to yield new immunotherapeutic strategies for
allergic diseases.
CONVENTIONAL TH2 CELLS IN ASTHMA
DEVELOPMENT
In the conventional instructive model of helper T cell
differentiation, IL-12 and IFN-γ induces the differen-
tiation of Th1 cells and IL-4 has an essential role for
transition from Th0 cells to Th2 cells, which provide a
clear prospect for molecular mechanism of immune
deviation. Consequently, helper T cell differentiation
turned out to be unexpectedly flexible and to be es-
tablished after stimulation by both specific antigen
and cytokine microenvironment. Although recent
studies demonstrated that Th1 cells do not always
cross-regulate Th2 cells,11 considerable evidence sug-
gests that CD4+ T cells and Th2 cytokines are major
players in the pathogenesis of airway inflammation in
asthma.12 Elevated numbers of T cells have been
identified in the bronchoalveolar lavage (BAL) fluid
and bronchial biopsy specimens from asthmatic pa-
tients and these T cells are predominantly CD4+ T
cell subset. Direct evidence of a pathogenic role for
CD4+ T cells in the development of asthma was first
demonstrated in a murine model of allergen-induced
allergic airway inflammation, where in vivo depletion
of CD4+ T cells by anti-CD4 monoclonal antibody be-
fore antigen challenge prevented both airway AHR
and eosinophilic infiltration.13 CD4+ T cells increased
in the airway of asthma patients express activation
markers including CD25 and MHC class II and pro-
duce IL-4, IL-5, and IL-13. These cytokines maintain
and amplify the Th2 polarization of T cell response,
stimulate class switching of B cells to IgE production,
and promote eosinophilic expansion and activation,
leading to asthma. Intriguingly, a number of studies
pointed out that most of phenotypic characteristics of
conventional CD4+ T cells described above are appli-
cable to those of iNKT cells. Therefore, the involve-
ment of iNKT cells in asthma may have been under-
estimated in the past studies. The authors will review
the general property of iNKT cells in the next section.
VERSATILE INKT CELLS: MULTI-POTENTIAL
IMMUNOMODULATOR
iNKT cells constitute a unique and evolutionally-
conserved subpopulation of T lymphocytes that ex-
press both T cell receptor (TCR) and NK receptors
such as NK1.1 or Ly49 in mice and CD161 in hu-
man.14-16 iNKT cells recognize glycolipid antigens by
an invariant TCRα chain composed of Vα14-Jα18 seg-
ments in mice and Vα24-Jα18 segments in humans,
and is associated with TCRβ chains using a restricted
set of Vβ genes (Fig. 1). Experimentally, these cells
could be detected by staining with CD1d tetramer
preloaded with α-galactosylceramide (αGC), which is
currently prerequisite for describing the term ‘iNKT
cells’.17 Most of iNKT cells are either CD4+ or double
negative (DN) and are characterized by a pre-
activated phenotype, being CD69+, CD62Llow, and
CD44high and secrete a large amount of cytokines in-
cluding IL-4 and IFN-γ in a few hours after stimulation
with either by anti-CD3 antibody or αGC in vivo, the
feature of which is a good contrast with conventional
T cells quiescent in the absence of encounter with
specific antigens in vivo. In fact, activated iNKT cells
are one of the most potent immune modulators
through a massive production of a various cytokines
including IL-4 and IFN-γ and were the major source
of cytokines among TCR-bearing cells after stimula-
tion with anti-CD3 antibody in vivo. iNKT cells have
been shown to recognize both exogenous and endo-
genous glycolipid molecules with a variety of struc-
tural trait. The most potent glycolipid antigens for
iNKT cells to date is αGC,18 a marine sponge-derived
glycosphingolipid with immunomodulatory activities
that is being exploited for immune-based therapeutic
iNKT Cells in Asthma
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Fig. 1 Phenotypic overview of iNKT cel and its suggested functional properties. NKT 
cels express invariant TCR α chain (Vα14 in mouse and Vα24 in human) and recognize 
glycolipid ligand presented by CD1d on antigen presenting cels. iNKT cels are potent to 
produce a wide variety of cytokines, which enable iNKT cels to be involved in many immu
noregulatory phases including alergy.
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intervention of diseases. In addition to their con-
served TCR usage, wide-spread distribution in all in-
dividuals, and their potent ability to produce a variety
of cytokines, iNKT cells recognize glycolipid antigens
in the context of MHC class I-like molecule, CD1d,
which is non-polymorphic and well-conserved both in
mouse and human.19 Therefore, iNKT cells could be
a promising target for immune-based therapies for
autoimmune diseases, tumor, and infection (Fig. 1), if
a proper manipulation of pleiotropic functions of
iNKT cells is available, for example, by modifying the
structure of prototypic glycolipid antigen, αGC. The
authors have previously demonstrated that OCH, a
sphingosine-truncated analogue of αGC, preferen-
tially induced Th2 cytokines from iNKT cells and ad-
ministration of OCH suppressed Th1-dominant auto-
immune disease models such as experimental auto-
immune encephalomyelitis (EAE), collagen-induced
arthritis (CIA), type I diabetes (TID) in non-obese
diabetes (NOD) mice, and dextran sulfate sodium
(DSS)-induced experimental colitis by inducing a
Th2-bias of autoantigen reactive T cells.20-23 Selective
regulation of cytokine production from iNKT cells by
using modified glycolipid ligands may expand the
possible application of glycolipid therapy beyond
autoimmune diseases.24
Besides the notion that iNKT cells are one of the
most attractive targets for manipulation of immune
response by appropriated glycolipid antigens in vivo,
there has also been tremendous progress in under-
standing pathophysiological roles of iNKT cells by
analyzing immune responses in Jα18-deficient mice,
which genetically lack iNKT cell population.25 iNKT
cells contribute to antitumor immunity and antimicro-
bial host responses in bacterial, parasitic, viral, and
fungal infections in several models mostly through
their IFN-γ-mediated NK cell activation. In addition,
iNKT cells have been shown to regulate autoimmu-
nity such as TID in NOD mice and EAE.26 Mean-
while, we have demonstrated that iNKT cells were in-
volved in the pathogenesis of arthritis by augmenting
autoantibody-mediated inflammation and inflamma-
tory immune response against type II collagen.27 In
addition, iNKT cells also participate in pathologic
processes such as oxazolone colitis,28 maternal intol-
erance of the fetus,29 and formation of atherosclerotic
plaque.30,31 Therefore, iNKT cells are a double-edged
sword, which enhance or suppress disease course de-
pending on the immune condition of host. Interest-
ingly, recent studies demonstrated the potent patho-
genic roles of iNKT cells in the development of bron-
chial asthma.
iNKT cells are pre-activated in vivo by continuously
encountering with endogenous lipid antigen(s) such
Oki S et al.
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Fig. 2 Two possible pathways for iNKT cel-dependent airway inflammation. See text for details.
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as lysosomal glycosphingolipid, isoglobotrihexosylce-
ramide (iGb3).32 iNKT cells are prepared for forth-
coming rapid production of regulatory cytokines by
environmental trigger such as IL-12 and Toll-like re-
ceptor (TLR) ligand, direct recognition of exogenous
glycolipid antigens, and antigen-specific activation of
conventional T cell to control entire immune re-
sponses. Considering ceaseless encounter of iNKT
cells with endogenous glycolipid antigen(s) to main-
tain pre-activated status of iNKT cells, one should
consider that local infection or inflammation caused
by irrelevant immune activation may influence iNKT
cell responses, resulted in unexpectedly skewed cy-
tokine production by these cells. Regarding local in-
fection, a couple of microorganism-derived exoge-
nous iNKT cell agonist has been reported to date.
α-glucuronosylceramide (GSL-1 ) and α-
galacturonosyl ceramide (GSL-1’) derived from
Sphingomonas species of α-proteobacteria are shown
to stimulate murine and human iNKT cells in a CD1d-
dependent manner.33,34 More recently, iNKT cells
were demonstrated to exert protective activity against
pathogenic Borrelia species of Spirohaetaceae family
by recognizing bacterial cell wall-derived α-
galactosyl-diacylglycerolipids.35 In addition to the rec-
ognition of microorganism-derived exogenous glycol-
ipids, activation of TLR expressed on dendritic cells
after bacterial infection results in massive IL-12 pro-
duction and local inflammation, leading to altered be-
havior of iNKT cells. Weak responses to putative self
antigens could be amplified by IL-12 produced by
dendritic cells (DCs) in response to microbial prod-
ucts, leading to augmented IFN-γ secretion.36 In fact,
we have also clearly demonstrated that pattern of cy-
tokine production by iNKT cells were greatly affected
by local or systemic administration of TLR agonists.37
Therefore, activation of iNKT cells is achieved
through either direct recognition of specific antigens
derived from infectious microorganisms or indirect
augmentation of iNKT cells responses to endogenous
antigens under specific (i.e. IL-12-rich) condition
(Fig. 2).
INVOLVEMENT OF INKT CELLS IN THE DE-
VELOPMENT OF ALLERGIC RESONSES
Given the outstanding ability to secrete a large
amount of regulatory cytokines in exogenous
antigen-dependent or -independent manner, versatile
iNKT cells has been shown to be involved in diverse
immune responses and immunological disorders.
Relevance of iNKT cells on the development of aller-
gic response was originally demonstrated almost a
decade ago employing iNKT cell-deficient β2 mi-
crogloblin (β2m) knockout mice, in which NK1.1+ T
cells were shown to be essential not only for the in-
duction of IL-4-producing helper T cells, but also for
IL-4-dependent class switching to immunoglobulin E
in response to injection of anti-IgD antibody.38 How-
ever, following studies did not always support the in-
volvement of iNKT cell in IgE production.39-42 CD1-
deficient mice or Jα18-deficient mice lacking iNKT
cells could mount a typical Th2 response to produce
iNKT Cells in Asthma
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IgE after immunization with anti-IgD antibody. Fur-
thermore, even β2m-deficient mice were shown to de-
velop functional type 2 immune responses by immu-
nization with ovalubmin (OVA), infection with
Leishmania major or Nippostrongylus brasiliensis.
These paradoxical results may reflect intrinsic com-
plexity of the development of allergic responses
where a diverse subset of immune cells could be pri-
mary IL-4 producer depending on different antigens,
route of administration, and so on. In this connection,
relatively common phospholipids such as phosphati-
dyl choline (PC) and phosphatidyl ethanolamine (PE)
extracted from cypress grains induce proliferation of
T cells derived from cypress-sensitive subjects.43
Even though recognition of phospholipids involved
CD4+ TCRαβ+ T cells that occur in a CD1ad-
dependent manner, Vα24+ human iNKT cells were
rare in phospholipid-specific T cell clones in contrast
to rather strong reactivity of murine Vα14 iNKT cell
hybridomas to purified PE, phosphatidylglycerol
(PG), and phosphatidyl inositol (PI). Interestingly,
these T cell clones specifically respond to phospholip-
ids derived from cypress pollen, but not phosphatidyl
choline from brain, liver, or egg. Furthermore, aller-
gic subjects displayed circulating antigen-specific
IgE, cutaneous weal and flare reactions to phosphol-
ipids that may not require CD161+ NKT cells. Al-
though it is clear that iNKT cells are not required for
all immune responses leading to IgE production, fur-
ther scrutiny will dissolve the conflicting evidence ar-
gued above for the involvement of iNKT cells on IgE
responses in vivo.
Although the systemic allergic responses were too
complex to clearly determine the involvement of
iNKT cells, the development of OVA-induced allergic
airway inflammation was shown to be impaired in the
absence of iNKT cells in either Jα18-deficient or in
CD1d-deficient mice.44 The lack of AHR in these mice
was associated with reduction of airway eosinophilia
as indicated by a reduction of eosinophils in BAL
fluid, reduction of OVA-specific IgE in their sera, and
reduction of IL-4 and IL-13 production from their
bronchial lymph node T cells. Interestingly, number
of iNKT cells in the lungs of wild type mice was
shown to be increased on airway challenge with OVA
and these pulmonary iNKT cells were capable of pro-
ducing IL-4 and IL-13 predominantly. Adoptive trans-
fer of IL-4IL-13-producing iNKT cells could restore
the impaired AHR, demonstrating the essential roles
of these cytokines produced by iNKT cells in the de-
velopment of asthma. Furthermore, airway eosino-
philia and mucus overproduction induced by ragweed
were significantly reduced in CD1-deficient mice and
the phenotype of these mice was well correlated with
significantly lower IL-4 production and lower eotaxin
responses in the airways.45 Furthermore, activation of
pulmonary iNKT cells by intranasal administration of
αGC or Sphingomonas-derived bacterial glycolipid is
sufficient for the development of AHR, eosinophilic
infiltration in the absence of conventional CD4+ T
cells and adaptive immunity.46 MHC class II-deficient
mice, which lack conventional CD4+ T cells, showed
exacerbation of AHR when intranasally challenged
with αGC, indicating that iNKT cells are not only a
modifier of AHR by producing cytokines to influence
adaptive immunity, but are also critical effector cells
for the development of AHR. These results clearly de-
scribe the role of iNKT cells in the pathogenesis of al-
lergic asthma in experimental murine models.
As one could easily anticipate from the phenotypic
similarity between murine and human iNKT cells,
two papers suggesting the involvement of iNKT cells
in the development of asthma have been published
recently. Firstly, Vα24 iNKT cells derived from pe-
ripheral blood of patients with allergic asthma ex-
press CCR9 at high frequency.47 CCR9 is commonly
expressed on mucosa-homing lymphocytes concomi-
tant with expression of α4β7, which promotes adhe-
sion to MAdCAM-1 on mucosal vessels. Massive ac-
cumulation of CCR9high iNKT cells in bronchial mu-
cosa occurs in asthma patients and the numbers of
CCR9+ iNKT cells from the peripheral blood of pa-
tients with asthma decreased either when they are as-
ymptomatic or when steroid treatment is effective.
CCR9 ligand CCL25 is shown to promote the recruit-
ment of CCR9-expressing iNKT cells into the lung to
develop allergic asthma. CCL25CCR9 interaction in-
duces phosphorylation of CD226 (DNAM-1) overex-
pressed on iNKT cells in asthma patients. CD226 en-
gagement is required for iNKT cells to induce Th2
bias of conventional T cells because iNKT cell func-
tion for Th2 skewing is impaired by inhibition of
CD226. Secondary, Akbari et al. reported that more
than 60% of CD3+ or CD4+ T cells from patients with
moderate-to-severe persistent asthma were the invari-
ant T cell receptor-bearing Vα24 iNKT cells detected
by αGC-loaded CD1d tetramer.48 iNKT cell derived
from airway produced IL-4 and IL-13, but not IFN-γ
upon stimulation with αGC. Massive infiltration of
iNKT cells is specific for asthma because the most
CD4+ T cells found in the lungs of patients with sar-
coidosis were conventional T cells. Detailed examina-
tion of bronchial biopsy specimens from the patients
with asthma revealed that nearly all the lamina prop-
ria lymphocytes expressed CD4 and Vα24 invariant
TCR. Intriguingly, the vast majority of the iNKT cells
coexpressed CD4+ in the BAL fluid of patient with
asthma, whereas approximately 50% of the iNKT cells
in peripheral blood were double-negative (CD4－
CD8−). CD4+ iNKT cells producing Th2 cytokines
may be selectively recruited into the lungs of patients
with bronchial asthma through the selective induc-
tion of CCR9 in circulating iNKT cells. Taken to-
gether, these two reports provided strong evidences
to suggest the involvement of iNKT cells in the patho-
genesis of allergic asthma not only in experimental
Oki S et al.
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Fig. 3 Implication for the possible target for treatment of asthma. 1. Prevention of activa-
tion of iNKT cels by blocking Vα24. 2. Prevention of entry of the activated pulmonary iNKT 
cels into airway mucosa by inhibiting CCL25 or CCR9. 3. Prevention of Th2 polarization of 
conventional CD4 ＋T cels by inhibiting cel-cel contact-driven phosphorylation of CD226. 
4. Stimulation of iNKT cels with synthetic glycolipid ligand(s) that inhibit Th2-skewing iNKT 
cel function
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murine model, but also in human diseases. CD4+
iNKT cells and conventional CD4+ T cells have a
number of shared phenotypes somewhat hard to dis-
criminate each other. Even though antigen-specific T
cell response is essential for initiation of asthmatic
diseases, iNKT cells might have been underesti-
mated in a number of past studies to show that con-
ventional Th2 cells play a predominant role in every
step of asthmatic diseases. For example, human
iNKT clones cultured with irradiated antigen-
presenting cells in the presence of IL-2 exert selective
IL-5 production in the absence of exogenous anti-
gens, implying direct roles of iNKT cell on eosino-
philia (unpublished observation). Therefore, the in-
volvement of iNKT cells in the pathogenesis or en-
hancement of asthma should be re-evaluated.
THERAPEUTIC POTENTIALS OF GLYCOL-
IPID LIGANDS FOR INKT CELLS FOR AL-
LERGIC ASTHMA
The findings that iNKT cells are involved in the de-
velopment of allergic asthma called people’s attention
to apply glycolipid ligands for modification of iNKT
cell function and possible intervention of allergic dis-
eases. In fact, there are many reports describing the
effects of αGC on murine experimental allergic
asthma model. Some of them provide the data to sup-
port the application of αGC for glycolipid therapy of
asthma but the others do not. A single intravenous or
intranasal injection of αGC just before the first anti-
gen challenge of sensitized mice was shown to abro-
gates elicitation of AHR, airway eosinophilia, IL-4 and
IL-5 level in BAL fluid and the serum level of OVA-
specific IgE.49 IL-13 production and goblet cell hyper-
plasia was inhibited as well by an intraperitoneal in-
jection of αGC.50 The therapeutic effects of αGC are
associated with a shift of cytokine response from Th2
to Th1 in BAL fluid and IFN-γ has been shown to play
a pivotal role for the effects of αGC. Therefore, αGC
injection at the time of antigen challenge could pro-
tect host from the development of typical asthmatic
symptoms. However, the development of AHR by in-
tranasal administration of αGC might be a concern as
a side effect. Repeated exposure of mice to αGC has
been shown to induce Th2 polarization by reducing
levels of IFN-γ and the protocol of continuous admini-
stration of αGC during sensitization with antigen ac-
tually increased antigen-specific IgE levels in serum
and worsened eosinophilic infiltration into lung.51 In
addition, intranasal coadministration of allergen and
αGC induced AHR, eosinophilic infiltration, elevation
of IgE level, and production of Th2 cytokines.52 Con-
sidering the outstanding ability of iNKT cells for the
production of a variety of cytokines, iNKT cells are a
iNKT Cells in Asthma
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double-edged sword, which enhance or suppress dis-
ease course depending on the immune condition of
host and application of glycolipid ligands for iNKT
cells on therapeutic intervention of asthma should be
given a particularly careful attention on potential risk
of the compound.
We have been screening α-GC analogues to select
glycolipid(s) other than αGC that have potent thera-
peutic effects on murine experimental asthma model
hopefully without exerting side effects. We have iden-
tified a novel synthetic glycolipid that inhibit Th2 cy-
tokine production (IL-4, IL-5, IL-13), eosinophilic infil-
tration goblet cell hyperplasia when administrated be-
fore the antigen challenge. The effector mechanism
of this novel glycolipid is not clear yet and detailed
analysis is now under investigation. As growing evi-
dences have supported the involvement of iNKT cells
in allergic asthma, a search for glycolipid antigens for
iNKT cells to manipulate the pleiotropic functions will
provide a novel and unique therapeutic approach for
allergic asthma.
CONCLUSIONS
In this review, we overviewed current understanding
of the pathophysiologic roles of iNKT cells in asthma.
We also discussed on possible therapeutic ap-
proaches for asthma employing glycolipid ligand for
iNKT cells (Fig. 3). Over the past several years, we
have learned more about specific mechanisms caus-
ing allergic inflammation such as TSLP and IL-25,
which has led to novel strategies for the treatment of
asthmatic diseases. The activation of innate immune
response for the inhibition of allergy is of particular
interest. For example, CpG oligodeoxynucleotides, a
TLR9 ligand, inhibit Th2 cytokine production. Inter-
estingly, intestinal commensal flora might provide
anti-allergic effect by signaling through TLR4. TLR4-
deficient mice were more susceptible to food allergy
and stimulation by intestinal microbes influences sus-
ceptibility to food allergy.53 Moreover, administration
of antibiotics converted allergy-resistant wild type
mice to allergy-susceptible. These data suggest that
elimination of commensal bacteria prevents develop-
ment of oral tolerance to allergens, and enhances al-
lergic sensitization. We have recently reported the
protective roles of another invariant NKT (Vα19
iNKT) cells for the development of EAE.54 Vα19
iNKT cells are functionally overlapping with mucosa-
associated invariant T (MAIT) cells.55,56 On the anal-
ogy of functional involvement of iNKT (Vα14 in
mouse, or Vα24 in human) cells, mucosa-associated
second iNKT subset might have functional relevance
on the development of asthma. Taken together, func-
tional manipulation of iNKT cells by specific glycol-
ipid ligands will provide a novel approach for the de-
velopment of new therapeutic strategy for allergy and
asthma.
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